| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P, F |
| Pretreatment |
EDTA |
| Positive control |
Infected tissue |
| Dilution |
1:25 - 1:100 |
| Isotype |
IgG |
| Localization |
Cell wall |
Toxoplasma gondii
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK068-05 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Toxoplasma Gondii infected tissue. |
| Dilution |
1:10 - 1:30 |
| Isotype |
IgG |
| Immunogen |
Toxoplasma gondii |
| Localization |
Organisms |
Toxoplasma gondii
|
Zeta Corporation |
polyclonal |
1.0 ml |
Concentrate |
RUO |
Z2556RL-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Toxoplasma Gondii infected tissue. |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Toxoplasma gondii |
| Localization |
Organisms |
Toxoplasma gondii
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
RUO |
Z2556RP-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Toxoplasma Gondii infected tissue. |
| Dilution |
1:10 - 1:30 |
| Isotype |
IgG |
| Immunogen |
Toxoplasma gondii |
| Localization |
Organisms |
Toxoplasma gondii
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
RUO |
Z2556RS-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Toxoplasma Gondii infected tissue. |
| Dilution |
1:10 - 1:30 |
| Isotype |
IgG |
| Immunogen |
Toxoplasma gondii |
| Localization |
Organisms |
Toxoplasma gondii
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
RUO |
Z2556RT-R |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM174 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Hairy cell leukemia. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant full-length human ACP5 protein |
| Localization |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
1 ml |
Concentrate |
CE/IVD |
Z2486ML |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM174 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Hairy cell leukemia. |
| Dilution |
- |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant full-length human ACP5 protein |
| Localization |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
7 ml |
Ready-to-use |
CE/IVD |
Z2486MP |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM174 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Hairy cell leukemia. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant full-length human ACP5 protein |
| Localization |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
0.5 ml |
Concentrate |
CE/IVD |
Z2486MS |
-
|
| Host |
Monospecific Mouse |
| Clone |
ZM174 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Hairy cell leukemia. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant full-length human ACP5 protein |
| Localization |
Cytoplasm |
TRAcP
|
Zeta Corporation |
ZM174 |
0.1 ml |
Concentrate |
CE/IVD |
Z2486MT |
-
|
| Host |
Rabbit |
| Clone |
ZR243 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon cancer |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Localization |
cell membrane |
TRAcP
|
Zeta Corporation |
ZR243 |
0.1 ml |
Concentrate |
CE/IVD |
Z2714RT |
-
|
| Host |
Mouse |
| Clone |
5G63 |
| Format |
Culture Supernatant |
| Method |
IHC(P) |
| Pretreatment |
Citrat pH 6.0 |
| Positive control |
Placenta |
| Dilution |
1:20 - 1:40 |
| Isotype |
mouse |
Transferrin Receptor (CD71)
|
Zytomed Systems GmbH |
5G63 |
500 µL |
Culture Supernatant |
RUO |
103-2299 |
-
|
| Host |
Mouse |
| Clone |
TB21 |
| Format |
Purified |
| Method |
F, P, EL |
| Positive control |
Human breast carcinoma |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human transforming groth factor beta 1 from platelets |
Transforming Growth Factor beta (TGFb)
|
Zytomed Systems GmbH |
TB21 |
100 µg |
Purified |
RUO |
620-0255 |
-
|
| Host |
Mouse |
| Clone |
TB21 |
| Format |
Purified |
| Method |
F, P |
| Positive control |
Human breast carcinoma |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human transforming groth factor beta 1 from platelets |
Transforming Growth Factor beta (TGFb)
|
Zytomed Systems GmbH |
TB21 |
10 µg |
Purified |
RUO |
620-0256 |
-
|
| Host |
Mouse |
| Clone |
CUB7402 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Breast Carcinoma |
| Dilution |
1:50 - 1:75 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
1 ml |
Concentrate |
CE/IVD |
MOB353 |
-
|
| Host |
Mouse |
| Clone |
CUB7402 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Breast Carcinoma |
| Dilution |
1:50 - 1:75 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
0.1 ml |
Concentrate |
CE/IVD |
MOB353-01 |
-
|
| Host |
Mouse |
| Clone |
CUB7402 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Breast Carcinoma |
| Dilution |
1:50 - 1:75 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasmic, Cell Membrane, Extracellular Matrix |
Transglutaminase II
|
Diagnostic Biosystems |
CUB7402 |
0.5 ml |
Concentrate |
CE/IVD |
MOB353-05 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
ER1 |
| Positive control |
Lymphoma, Tonsil |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cell membrane |
TRBC1
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
ALI3280G7 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
CC1 |
| Positive control |
Lymphoma, Tonsil |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cell membrane |
TRBC1
|
|
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
AVI3280G |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Purified |
| Method |
P, IF |
| Pretreatment |
Citrate |
| Positive control |
infected tissue |
| Isotype |
Rabbit IgG |
| Immunogen |
Native, purified |
Treponema pallidum
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
620-0262 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Dilution |
1:100 - 1:200 |
| Immunogen |
Treponema pallidum |
| Localization |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
1ml |
Concentrate |
RUO |
Z2554RL-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Dilution |
- |
| Immunogen |
Treponema pallidum |
| Localization |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
RUO |
Z2554RP-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Dilution |
1:100 - 1:200 |
| Immunogen |
Treponema pallidum |
| Localization |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
RUO |
Z2554RS-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Dilution |
1:100 - 1:200 |
| Immunogen |
Treponema pallidum |
| Localization |
Organisms |
Treponema pallidum
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
RUO |
Z2554RT-R |
-
|
| Host |
Mouse |
| Clone |
1306/156 |
| Format |
Purified |
| Method |
EL |
| Isotype |
Mouse IgG1 |
| Immunogen |
Native |
Trichomonas vaginalis (Strain 1)
|
Zytomed Systems GmbH |
1306/156 |
200 µg |
Purified |
RUO |
620-0265 |
-
|
| Host |
Rabbit |
| Clone |
EPR17341 |
| Format |
Concentrate |
| Method |
P, IF, WB |
| Pretreatment |
EDTA |
| Positive control |
Astrocytoma, cerebral cortex tissue |
| Dilution |
1:500 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus. The exact sequence is proprietary. |
| Localization |
Cytoplasm |
TrkA + TrkB + TrkC
|
Abcam |
EPR17341 |
0.1 ml |
Concentrate |
RUO |
AB181560 |
-
|
| Host |
Rabbit |
| Clone |
SP293 |
| Format |
Concentrate |
| Reactivity |
MS |
| Method |
P, WB, FL |
| Pretreatment |
EDTA |
| Positive control |
Tonsil |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide derived from the C-terminus of human TROP-2 protein |
| Localization |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP293 |
0.5 ml |
Concentrate |
RUO |
520-5932 |
-
|
| Host |
Rabbit |
| Clone |
SP293 |
| Format |
Concentrate |
| Reactivity |
MS |
| Method |
P, WB, FL |
| Pretreatment |
EDTA |
| Positive control |
Tonsil |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide derived from the C-terminus of human TROP-2 protein |
| Localization |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP293 |
1 ml |
Concentrate |
RUO |
520-5934 |
-
|
| Host |
Rabbit |
| Clone |
SP294 |
| Format |
Concentrate |
| Reactivity |
MS |
| Method |
P, WB |
| Pretreatment |
EDTA |
| Positive control |
Tonsil |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide derived from the internal region of human TROP-2 protein |
| Localization |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP294 |
0.5 ml |
Concentrate |
RUO |
520-5942 |
-
|
| Host |
Rabbit |
| Clone |
SP294 |
| Format |
Concentrate |
| Reactivity |
MS |
| Method |
P, WB |
| Pretreatment |
EDTA |
| Positive control |
Tonsil |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide derived from the internal region of human TROP-2 protein |
| Localization |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP294 |
1 ml |
Concentrate |
RUO |
520-5944 |
-
|
| Host |
Rabbit |
| Clone |
SP295 |
| Format |
Concentrate |
| Reactivity |
MS |
| Method |
P, WB |
| Pretreatment |
EDTA |
| Positive control |
Tonsil |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide derived from the internal region of human TROP-2 protein |
| Localization |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP295 |
0.5 ml |
Concentrate |
RUO |
520-5952 |
-
|
| Host |
Rabbit |
| Clone |
SP295 |
| Format |
Concentrate |
| Reactivity |
MS |
| Method |
P, WB |
| Pretreatment |
EDTA |
| Positive control |
Tonsil |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide derived from the internal region of human TROP-2 protein |
| Localization |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP295 |
1 ml |
Concentrate |
RUO |
520-5954 |
-
|
| Host |
Rabbit |
| Clone |
ZR388 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Breast or colon carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
| Localization |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
1 ml |
Concentrate |
CE/IVD |
Z2744RL |
-
|
| Host |
Rabbit |
| Clone |
ZR388 |
| Format |
ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Breast or colon carcinoma |
| Dilution |
--- |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
| Localization |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
7 ml |
ready-to-use |
CE/IVD |
Z2744RP |
-
|
| Host |
Rabbit |
| Clone |
ZR388 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Breast or colon carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
| Localization |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
0.5 ml |
Concentrate |
CE/IVD |
Z2744RS |
-
|
| Host |
Rabbit |
| Clone |
ZR388 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Breast or colon carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
| Localization |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
0.1 ml |
Concentrate |
CE/IVD |
Z2744RT |
-
|
| Host |
Rabbit |
| Clone |
ZR382 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal breast, breast carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
| Localization |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
1 ml |
Concentrate |
CE/IVD |
Z2673RL |
-
|
| Host |
Rabbit |
| Clone |
ZR382 |
| Format |
r-t-u |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal breast, breast carcinoma |
| Dilution |
gebrauchsfertig |
| Isotype |
IgG |
| Immunogen |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
| Localization |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
7 ml |
r-t-u |
CE/IVD |
Z2673RP |
-
|
| Host |
Rabbit |
| Clone |
ZR382 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal breast, breast carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
| Localization |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
0.5 ml |
Concentrate |
CE/IVD |
Z2673RS |
-
|
| Host |
Rabbit |
| Clone |
ZR382 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal breast, breast carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
| Localization |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
0.1 ml |
Concentrate |
CE/IVD |
Z2673RT |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P, WB, EL |
| Pretreatment |
Fast Enzyme, Pepsin |
| Positive control |
Pancreas |
| Dilution |
1:50 - 1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Purified trypsin from human pancreas |
| Localization |
Cytoplasmic, extracellular |
Trypsin (Human pancreatic)
|
Zytomed Systems GmbH |
polyclonal |
0.2 ml |
Concentrate |
RUO |
RBK055-02 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Anterior Pituitary |
| Dilution |
1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Purified human TSH |
| Localization |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
520-17500 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Anterior Pituitary |
| Dilution |
1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Purified human TSH |
| Localization |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
520-17502 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Anterior Pituitary |
| Dilution |
1:200 |
| Isotype |
Rabbit IgG |
| Immunogen |
Purified human TSH |
| Localization |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
520-17504 |
-
|
| Host |
Mouse |
| Clone |
8G7G3/1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal thyroid or lung. |
| Dilution |
1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Rat TTF-1 recombinant protein |
| Localization |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2069ML |
-
|
| Host |
Mouse |
| Clone |
8G7G3/1 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal thyroid or lung. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Rat TTF-1 recombinant protein |
| Localization |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2069MP |
-
|
| Host |
Mouse |
| Clone |
8G7G3/1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal thyroid or lung. |
| Dilution |
1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Rat TTF-1 recombinant protein |
| Localization |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2069MS |
-
|
| Host |
Mouse |
| Clone |
8G7G3/1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Normal thyroid or lung. |
| Dilution |
1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Rat TTF-1 recombinant protein |
| Localization |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2069MT |
-
|
| Host |
Mouse |
| Clone |
SPT24 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adeno-CA |
| Dilution |
1:100 - 1:200 |
| Isotype |
Mouse IgG1 kappa |
| Localization |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3126A |
-
|
| Host |
Mouse |
| Clone |
SPT24 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adeno-CA |
| Dilution |
1:100 - 1:200 |
| Isotype |
Mouse IgG1 kappa |
| Localization |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
1 ml |
Concentrate |
CE/IVD |
ACI3126C |
-
|
| Host |
Mouse |
| Clone |
SPT24 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adeno-CA |
| Dilution |
- |
| Isotype |
Mouse IgG1 kappa |
| Localization |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
6 ml |
Ready-to-use |
CE/IVD |
API3126AA |
-
|